The effect of IL-6 inhibitor (Tocilizumab) on the prognosis of covid-19 patients with acute respiratory failure hospitalized in Imam Reza Hospital in Tabriz
Phase 2
Recruiting
- Conditions
- COVID-19 disease.COVID-19 diseaseU07.1
- Registration Number
- IRCT20200406046968N1
- Lead Sponsor
- Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Age range 18-70
P/F<300
Negative IGRA test
IL-6>7
Exclusion Criteria
Acute or chronic renal failure
Increased liver enzymes 3 times normal with gastrointestinal symptoms or abdominal pain and nausea and jaundice or increased liver enzymes 5 times normal - liver cirrhosis
Pregnancy
latent TB
Active gastric ulcer
Dissatisfaction with entering the study
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentage of effect of Tocilizumab on COVID-19 patients. Timepoint: Patients receive the drug in a single dose over an hour, and resorption monitoring will be performed to improve oxygenation status and subsequent complications in vital organs of the heart, kidneys, CNS, hemodynamic disturbances, duration of mechanical ventilation, and eventual mortality. Method of measurement: Clinical and laboratory testing.
- Secondary Outcome Measures
Name Time Method